Estela Rodriguez: Patients excluded from most clinical trials does not help us find solutions with Leptomeningeal disease
Estela Rodriguez shared a post by EGFR Resisters on X/Twitter:
“Leptomeningeal disease – is one of the biggest areas of need and data in the management of patients with EGFR+ lung cancer. Patients excluded from most clinical trials which does not help us find solutions.”
Quoting EGFR Resisters’s post:
“Different genetic profiles contribute to worse overall survival in patients with leptomeningeal metastases of non-small-cell lung cancer ‘Patients with LM and TP53 mutations presented with worse OS. LM patients with EGFR had a shorter OS.’ ”
Visit the article website.
Source: Estela Rodriguez/X and EGFR Resisters/X
Estela Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials. Dr. Rodriguez is known to help empower women to take charge of their own healthcare and believes in the power of mentorship.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023